1.The relationship of platelet phospholipase A, and tumor
Ningsheng LIANG ; Zhenwen FANG
China Oncology 2000;0(06):-
Phospholipase A2(PLA2) is an enzyme family which widely distributed in nature. It is related to many important function in physiology and pathology. Among the enzymes, a small molecule PLA2 (platelet PLA2) is closely related to tumor. The study of platelet PLA2 and tumor is reviewed.
2.Postoperative radiation therapy in gastric cancer
China Oncology 2000;0(06):-
Radiation therapy or chemoradiation will be used much more commonly in the treatment of patients in postoperative gastric cancer . We have reviewed the indication, toxicity, radiation dose, radiation field in postradiotherapy of gastric cancer patients.
3.Prognostic factors of early stage non-small cell lung cancer
Zhiqin JIANG ; Guoliang JIANG ; Hao QIAN
China Oncology 2000;0(06):-
Local recurrences and distant metastases develop in patients with early stage NSCLC ( Non-small Cell Lung Cancer) after surgery. It becomes important to predict the prognosis and give postoperative adjuvant therapy if necessary. The advances of prognostic factors of early stage NSCLC are reviewed.
4.Clinical and pathological analysis of primary malignant lymphoma of the breast
China Oncology 2000;0(06):-
Purpose: To investigate the diagnosis, pathological characteristics and treatment of primary malignant lymphoma of the breast (PMLB). Methods: Clinical and pathological data of 16 cases of PMLB were analyzed retrospectively. Results: No case was correctly diagnosed before operation. All the 12 cases were operated and identified by pathology, in which total mastectomy, radical mastectomy and modified radical mastectomy were carried out in 5, 3 and 4 patients respectively. Moreover, all cases were combined with post-operative chemotherapy or radiotherapy. 10 cases were followed up 1 - 10 years. 4 cases who survived 22 months on the average died of the tumor spread and metastasis during follows-up, and the others are still alive. Especially, 1 case, recurring 2 times locally, has survived for 4. 5 years after reoperation. Conclusions: The final diagnosis of this disease depends on the pathological examination. The majority of PMLB is non-Hodgkins lymphoma ( NHL), and mostly of B cell origin and are mostly related to the mucosa-associated lymphoid tissue ( MALT). Total mastectomy or mastectomy plus axillary nodes dissection is the preferred method of operation and the adequate post-operative chemotherapy is very important.
5.The value of ~(99m)Tc-MIBI imaging in differentiating of breast masses
Min ZHANG ; Jian WU ; Feng HAN
China Oncology 2000;0(06):-
Purpose: To explore the clinical value of 99mTc-MIBI imaging in differentiating malignancies from benign breast masses. Methods: 195 patients underwent the examination for 99m Tc-MIBI. Comparative diagnosis was done by postoperative pathology in all cases. Results: 69 of the 84 cases of breast cancer were preoperatively diagnosed by 99mTc-MIBI, the causes of false-negative results were small size of the mass and the higher degree of malignancy. 102 of the 111 patients with benign lesions were scintimammographically negative, the cause of false-positive results was large fibroadenomas with surplus blood supply. The sensitivity was 82. 1%, specificity was 92.0%, and the diagnostic accuracy was 89.2%. Conclusions: 99mTc-MIBI examination is an effective, simple and noninvasive diagnostic method for primary breast cancer.
6.Clinical analysis of radiotherapy plus drug intra-cavitary infusion for 184 patients on carcinoma of the bladder after operation
China Oncology 2000;0(06):-
Purpose: In order to improve the treatment results of post-operative irradiation, a comparison is made between radiotherapy only and radiotherapy plus cisplatin infusion in the bladder after surgery for carcinoma of the bladder. Methods: 83 patients with carcinoma of the bladder were treated by radiotherapy plus cisplatin infusion of the bladder after surgery as study group and another 77 patients were treated with radiotherapy only as control group. Results: The 1-, 3- and 5 -year survival rates and no evidence of disease rates in study group were 97. 6% (81/83), 82. 7 % (67/81), 89. 6% (60/ 67) and 94.0%(78/83), 89. 7% (70/78) , 84. 3%(59 /70); they were 92. 2% (71/77), 84. 5% (60/71), 75.0% (45/60) and 88. 3% (68/77), 77.9% (53/68), 73. 6% (39/53) in the control group, respectively. The relapse and metastasis rates were 15.7% (13/83) and 8.4% (7/83) in study group;; 23.4% (18/77) and 18.2% (14/77) in the control group(P
7.Assessment on the efficacy of intraperitoneal chemotherapy on progressive gastric cancer after radical treatment
Cailian WANG ; Baoan CHEN ; Zao JIANG
China Oncology 2000;0(06):-
Purpose: To observe the efficacy of intraperitoneal chemotherapy on advanced gastric cancer after radical treatment. Methods: 64 cases of patients with stage Ⅱ - Ⅲ treated by radical surgery were selected and randomly divided into systematic plus intraperitoneal chemotherapy group and systemic chemotherapy group. 3-year survival rate and 3-year recurrence rate were recorded. Results: The recurrence rate for the intraperitoneal chemotherapy group was 18.75% while the control was 43. 33% (P
8.Clinical observation of oxaliplatin combination with 5-fluorouracil/folinic acid therapy in advanced colorectal cancer
Jian DING ; Jiansheng ZHUANG ; Xinmin LIN
China Oncology 2000;0(06):-
Purpose: To evaluate the effect and safety of combination chemotherapy with oxaliplatin( L-OHP) plus 5-fluorouracil(5-FU)/folinic acid( CF) in advanced colorectal cancer( ACRC). Methods: 31 patients with ACRC entered the study. L-OHP 130 mg/m2 , iv infusion for 4 hours on day 1; CF 200 mg/m2 , iv infusion for 2 hours followed by 5-FU 500mg/ m , iv infusion for 4 hours from day 1 to day 5, repeated every 3 weeks. Results: There were 10 partial responses, 7 stable disease, 9 progressive disease, the response rate being 38. 5% . The main adverse effect was neuro-sensory toxicity which was seen in 90. 3% of the patients. Vomitting and diarrhea was observed in 58. 1% and 45. 2% of the patients respectively. Bone marrow suppression was mild. Conclusions: L-OHP combination with 5-FU/CF yields an encouraging response with acceptable toxicity in our study. Furthermore clinical reseach is worthwhile.
9.Evaluation of jejunal interposition reconstruction P and SS type after total gastrectomy in patients with gastric carcinoma : reports of 31 cases
Qian QIN ; Hong LI ; Xingming DAI
China Oncology 2000;0(06):-
Purpose: To evaluate the therapeutic effect of the jejunal interposition reconstruction SS and P type after total gastrectomy in patients with gastric carcinoma. Methods: 31 cases with gastric carcinoma operated on from June, 1990 - Octuber, 2000 were retrospectively analyzed. After total gastrectomy 16 patients were operated by jejunal interposition reconstruction SS type and 15 a jejunal interposition reconstruction P type. The clinic materials of the two types of jejunal interposition reconstruction were assessed by 6 months -5 years follow-up. Results: 30 -60 minutes and 80 - 120 minutes Ba emptying time of SS and P type were 62. 5%, 66. 7% and 37. 5%, 33. 3% respectively ; BLA were 73. 6 + 1. 1% and 74. 4 + 1. 3% , respectively; HB were 15 +1.3 and 15 +1.5; The Visick scoring of the 87. 7% patients with S type and the 86. 7% patients with P type was Ⅰ - Ⅱ grades. Reflux oesophagitis of the patients with S type was 12. 5%. Conclusions: The jejunal interposition reconstruction SS and P type after total gastrectomy are effective means to improve quality of life and to reduce complications after gastrectomy and to maintain the canal of the chyme through the duodenal tract.
10.Paclitaxel combined with chemotherapy in the treatment of advanced breast cancer
Fengshou JIANG ; Yubei SUN ; Bing HU
China Oncology 2000;0(06):-
Purpose: To evaluate the therapeutic effect and toxicities of paclitaxel combined chemotherapy regimens in the treatment of advanced breast cancer. Methods: 30 cases with advanced breast cancer verified by pathology were given routinely standard anti-hypersensitive treatment before systematic chemotherapy. In combination regimens, Taxol was given 175 mg/m by intravenous( i. v.) infusion on dayl, cyclophosphamide 400mg/m i. v. on day 1, day 8, 5-fluouracil 500 mg/ m i. v. on day 1, day 8. Drugs were repeated every 28 days and one course consisted of 2 cycles. Results: 3 patients showed complete response and 16 patients showed partial response. The overall response rate was 63. 3%. The median duration of remission was 9 months. The major toxic effects including myelosuppression, myalgia/arthralgta and peripheral neuropathy, were mild or moderate. There was no hypersensitivity. The side-effects disappeared after stopping chemotherapy. Conclusions: Taxol combined with chemotherapy regimens are an effective treatment for patients with advanced breast cancer, The toxicity of the treatment are tolerated by the patients. These regimens are worthy of recommendation as second-line chemotherapy.